PTB
MCID: PLM001
MIFTS: 69

Pulmonary Tuberculosis (PTB)

Categories: Infectious diseases, Respiratory diseases

Aliases & Classifications for Pulmonary Tuberculosis

MalaCards integrated aliases for Pulmonary Tuberculosis:

Name: Pulmonary Tuberculosis 12 15 17
Tuberculosis, Pulmonary 73 44 70
Tuberculosis Pulmonary 54
Ptb 48

Classifications:



External Ids:

Disease Ontology 12 DOID:2957
ICD9CM 34 011
MeSH 44 D014397
NCIt 50 C26899
SNOMED-CT 67 81483001
ICD10 32 A15
UMLS 70 C0041327

Summaries for Pulmonary Tuberculosis

Disease Ontology : 12 A tuberculosis that is a contagious disease located in lungs. The infection has symptom fever, has symptom cough, has symptom difficulty in breathing, has symptom inflammatory infiltrations, has symptom formation of tubercles, has symptom caseation, has symptom pleural effusion, and has symptom fibrosis.

MalaCards based summary : Pulmonary Tuberculosis, also known as tuberculosis, pulmonary, is related to miliary tuberculosis and pneumoconiosis, and has symptoms including fever, cough and pleural effusion. An important gene associated with Pulmonary Tuberculosis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Calcium carbonate and Ethambutol have been mentioned in the context of this disorder. Affiliated tissues include lungs, liver and heart, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 73 Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria.... more...

Related Diseases for Pulmonary Tuberculosis

Diseases related to Pulmonary Tuberculosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1049)
# Related Disease Score Top Affiliating Genes
1 miliary tuberculosis 31.9 IL12RB1 IFNGR1 IFNG ADA
2 pneumoconiosis 31.4 IL4 IL10 HLA-DRB1
3 silicosis 31.3 IL4 IL18 IL10
4 purpura 31.3 IL4 IL10 IFNG
5 lung disease 31.2 TLR2 MBL2 IL4 IL18 IL10 IFNG
6 pneumonia 31.2 TLR2 MBL2 IL4 IL10 IFNG CCL3
7 pleurisy 31.1 TLR2 IL2 IFNG CCL3 ADA
8 erythema nodosum 31.1 VDR IL10 IFNG
9 tuberculous meningitis 31.0 TLR2 NAT2 CCL3 ADA
10 multidrug-resistant tuberculosis 31.0 VDR SLC11A1 INHA IL10 IFNG
11 appendicitis 31.0 IL2 IL10 IFNG
12 nocardiosis 30.9 IL12RB1 IFNG
13 bacterial pneumonia 30.9 TLR2 IL10 CCL3 ADA
14 aspergillosis 30.9 TLR2 MBL2 IL4 IL18 IL10 IFNG
15 leprosy 3 30.9 VDR TLR2 SLC11A1 IL4 IL2 IL10
16 viral hepatitis 30.9 TLR2 IL4 IL2 IL10 IFNG HLA-DRB1
17 bronchitis 30.9 TLR2 IL4 IL10
18 abdominal tuberculosis 30.8 IL12RB1 IFNG ADA
19 mycobacterium fortuitum 30.8 IL12RB1 IFNGR1
20 cryptococcosis 30.8 MBL2 IL4 IL10 IFNG
21 histoplasmosis 30.8 IL12RB1 IFNG HLA-DRB1
22 allergic bronchopulmonary aspergillosis 30.8 MBL2 IL4 IL10 IFNG HLA-DRB1
23 echinococcosis 30.8 TLR2 IL10 IFNG HLA-DRB1
24 severe acute respiratory syndrome 30.8 MBL2 IL10 IFNG
25 pulmonary disease, chronic obstructive 30.8 TLR2 IL4 IL10 CCL3
26 extrapulmonary tuberculosis 30.8 VDR TLR2 SLC11A1 MBL2 IL10 IFNGR1
27 candidiasis 30.7 TLR2 MBL2 IL4 IL2 IL10 IFNG
28 tuberculous peritonitis 30.7 IFNG ADA
29 erythema multiforme 30.7 IL4 IL2 IFNG
30 endocarditis 30.7 TLR2 IL10 IFNG
31 oral tuberculosis 30.7 IL2 IFNG
32 nontuberculous mycobacterial lung disease 30.7 TLR2 SLC11A1 IL12B HLA-DRB1
33 interstitial lung disease 30.7 IL4 IL18 IL10 IFNG
34 bronchopneumonia 30.7 IL10 HP CCL3
35 exanthem 30.6 IL2 IL18 IL10 IFNG
36 hypereosinophilic syndrome 30.6 IL4 IL2RA IL2 IFNG
37 filariasis 30.6 TLR2 IL2 IL10 IFNG
38 human immunodeficiency virus type 1 30.6 IL2 IL12B IL10 IFNG CCL3 ADA
39 hepatitis b 30.6 TLR2 MBL2 IFNGR1 IFNG HLA-DRB1
40 bacterial infectious disease 30.5 TLR2 SLC11A1 MBL2 IL18 IL10 IFNG
41 ige responsiveness, atopic 30.5 IL4 IL10 IFNG
42 herpes zoster 30.5 TLR2 IL2 IL10 IFNG HLA-DRB1
43 allergic disease 30.5 TLR2 IL4 IL2 IL18 IL12RB1 IL10
44 hepatitis a 30.5 IL4 IL10 IFNG
45 disease by infectious agent 30.5 TLR2 SLC11A1 MBL2 IL4 IL2 IL18
46 lymphopenia 30.5 IL4 IL2RA IL2 IL10 IFNG ADA
47 bronchial disease 30.4 TLR2 IL4 IL2 IL10 IFNGR1 IFNG
48 toxoplasmosis 30.4 TLR2 IL4 IL10 IFNGR1 IFNG CCL3
49 amebiasis 30.4 TLR2 IL4 IL10
50 skin sarcoidosis 30.4 IL2 IFNG

Comorbidity relations with Pulmonary Tuberculosis via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchiectasis
Bronchitis Deficiency Anemia
Heart Disease Iron Deficiency Anemia
Pleural Tuberculosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure

Graphical network of the top 20 diseases related to Pulmonary Tuberculosis:



Diseases related to Pulmonary Tuberculosis

Symptoms & Phenotypes for Pulmonary Tuberculosis

Symptoms:

12
  • fever
  • cough
  • pleural effusion
  • difficulty in breathing
  • inflammatory infiltrations
  • formation of tubercles
  • caseation
  • fibrosis

UMLS symptoms related to Pulmonary Tuberculosis:


hemoptysis

MGI Mouse Phenotypes related to Pulmonary Tuberculosis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 ADA HP IFNG IFNGR1 IL10 IL12B
2 homeostasis/metabolism MP:0005376 10.36 ADA HP IFNG IFNGR1 IL10 IL12B
3 immune system MP:0005387 10.34 ADA HP IFNG IFNGR1 IL10 IL12B
4 digestive/alimentary MP:0005381 10.32 ADA IFNG IFNGR1 IL10 IL12B IL18
5 cardiovascular system MP:0005385 10.26 ADA HP IFNG IFNGR1 IL10 IL18
6 endocrine/exocrine gland MP:0005379 10.19 ADA IFNG IFNGR1 IL10 IL2 IL2RA
7 mortality/aging MP:0010768 10.17 ADA HP IFNG IFNGR1 IL10 IL12B
8 integument MP:0010771 10.06 IFNG IFNGR1 IL10 IL12RB1 IL18 IL4
9 liver/biliary system MP:0005370 10.02 ADA HP IFNG IFNGR1 IL10 IL2
10 neoplasm MP:0002006 9.91 HP IFNG IFNGR1 IL10 IL12B IL2
11 renal/urinary system MP:0005367 9.76 ADA HP IFNG IFNGR1 IL4 MBL2
12 respiratory system MP:0005388 9.56 ADA IFNG IL10 IL12B IL2 IL2RA
13 skeleton MP:0005390 9.4 ADA IFNG IFNGR1 IL10 IL12B IL12RB1

Drugs & Therapeutics for Pulmonary Tuberculosis

Drugs for Pulmonary Tuberculosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium carbonate Approved, Investigational Phase 4 471-34-1
2
Ethambutol Approved Phase 4 74-55-5 3279 14052
3
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
4 Interleukin-2 Phase 4
5 Antibiotics, Antitubercular Phase 4
6 Antimetabolites Phase 4
7 Anti-Bacterial Agents Phase 4
8 Antitubercular Agents Phase 4
9 Lipid Regulating Agents Phase 4
10 Anti-Infective Agents Phase 4
11 Hypolipidemic Agents Phase 4
12
Gatifloxacin Approved, Investigational Phase 3 112811-59-3 5379
13
Zinc sulfate Approved, Investigational Phase 3 7733-02-0
14
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
15
Copper Approved, Investigational Phase 3 7440-50-8 27099
16
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
17
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
18
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
19
Zinc Approved, Investigational Phase 3 7440-66-6 32051
20
Nicotine Approved Phase 3 54-11-5 942 89594
21
Nitric Oxide Approved Phase 3 10102-43-9 145068
22
Permethrin Approved, Investigational Phase 3 52645-53-1 40326
23
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
24
Tocopherol Approved, Investigational Phase 3 1406-66-2
25
Rifapentine Approved, Investigational Phase 2, Phase 3 61379-65-5 6323497
26
Atorvastatin Approved Phase 2, Phase 3 134523-00-5 60823
27
Moxifloxacin Approved, Investigational Phase 2, Phase 3 354812-41-2, 151096-09-2 152946
28
Bedaquiline Approved Phase 2, Phase 3 843663-66-1
29
Linezolid Approved, Investigational Phase 2, Phase 3 165800-03-3 441401
30
Clofazimine Approved, Investigational Phase 2, Phase 3 2030-63-9 2794
31
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
32
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
34
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
35
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
36
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
37
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 3 83-88-5 493570
38
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
39
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 70-16-6, 59-43-8 1130
40
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4 445354
41
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
42
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
43
Cobalamin Experimental Phase 3 13408-78-1 6857388
44 Tocotrienol Investigational Phase 3 6829-55-6
45 Liver Extracts Phase 2, Phase 3
46 Ophthalmic Solutions Phase 3
47 Zinc Supplement Phase 3
48 Micronutrients Phase 3
49 Trace Elements Phase 3
50 Vitamins Phase 3

Interventional clinical trials:

(show top 50) (show all 245)
# Name Status NCT ID Phase Drugs
1 Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority Trial Unknown status NCT02901288 Phase 4 Isoniazid;Rifampicin;Pyrazinamide;Ethambutol;Levofloxacin
2 The Impact of the Simple Verbal Intervention for Adequately Collecting Sputum and the Acceptable Specimen Based on Gram Stain, on the Results of Sputum Acid-fast Bacilli Smear Testing Unknown status NCT01135043 Phase 4
3 New Super-short Course Regimen for Retreatment Pulmonary Tuberculosis Unknown status NCT02331823 Phase 4 Isoniazid Aminosalicylate Tablets;Streptomycin injectable
4 International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
5 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis (EVIDENT Study): a Randomized, Double Blind, Controlled Trial Unknown status NCT02169570 Phase 4
6 Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis in the National Institute of Respiratory Diseases Unknown status NCT02464683 Phase 4
7 Different Reintroduction Regimens of Antituberculosis Drugs After Development of Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
8 Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) Completed NCT00298870 Phase 4 Isoniazid;isoniazed
9 Pilot Roll Out of the Xpert MTB/Rif for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil: a Stepped Wedge Trial Completed NCT01363765 Phase 4
10 Pilot Clinical Trial of PRS TB Regimen I - Phase II Completed NCT03561753 Phase 4 Group A (the standard 2HRZE/4HR regimen);Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
11 Multicenter Open Non-Comparative Clinical Study to Evaluate the Efficacy and Safety of Three Months TAVANIC Course (Levofloxacin) in Combine Treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB) Completed NCT00495339 Phase 4 Levofloxacin
12 A Randomised Control Trial on the Effectiveness of Three Modalities of Tuberculosis Treatment Supervision Under DOTS Strategy in Ethiopia. Completed NCT00939419 Phase 4
13 Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation: a National Multicenter Randomized Clinical Trial Completed NCT02231229 Phase 4 conventional therapy
14 A Randomized Multicenter Clinical Trial of a New Treatment for Primary Smear- Positive Pulmonary Tuberculosis With Interleukin-2 Recruiting NCT04766307 Phase 4 Interleukin-2
15 Primary Prophylaxis for Prevention of TB in Prison's Populations Terminated NCT03028129 Phase 4 Isoniazid 900 milligrams;Placebo
16 A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis Unknown status NCT00216385 Phase 3 Gatifloxacin combined regimen
17 Role of Oral Vitamin D as an Adjunct Therapy in Category I Pulmonary Tuberculosis Along With Assessment of Immunological Parameters. (Double-blind, Randomized, Placebo-Controlled, Clinical Trial) Unknown status NCT00507000 Phase 3 Cholecalciferol;Lactose granules
18 Characterization of Immune Responses in Treatment-induced Latency in Pulmonary Tuberculosis Unknown status NCT01154959 Phase 3 Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
19 Efficacy of Oral Zinc Administration as an Adjunct Therapy in Category I Pulmonary Tuberculosis Along With Assessment of Immunological Parameters (Double-blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial Unknown status NCT00698386 Phase 3
20 A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects With Pulmonary Tuberculosis Unknown status NCT02467608 Phase 2, Phase 3 Isoniazid with HUEXC030 and RZE;HRZE
21 A Randomized, Partially-blinded, Clinical Trial of Isoniazid and Rifapentine (3HP) Therapy to Prevent Pulmonary Tuberculosis in High-risk Individuals Identified by a Transcriptomic Correlate of Risk Unknown status NCT02735590 Phase 2, Phase 3 Isoniazid;Rifapentine
22 Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-label, Controlled Phase 3 Clinical Trial. TBTC Study 31, ACTG Study A5349 Unknown status NCT02410772 Phase 3 rifapentine;rifapentine and moxifloxacin;control
23 A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 4 and 6 Months of Treatment in Adult Subjects With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and After 6 Months of Treatment in Adult Subjects With Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis. Completed NCT02342886 Phase 3 Moxifloxacin;PA-824;Pyrazinamide;HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination);HR (rifampicin plus isoniazid combination tablets)
24 Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters Completed NCT00341328 Phase 3
25 TBTC Study 22: Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Twice-Weekly Rifampin and Isoniazid in the Continuation Phase of Therapy for Pulmonary Tuberculosis Completed NCT00023335 Phase 3 Rifapentine;Isoniazid
26 Efficacy and Safety Study of Immunomodulator (Mycobacterium w) as an Adjunct Therapy in Category-II Pulmonary Tuberculosis Along With Assessment of Immunological Parameters Completed NCT00265226 Phase 3
27 Micronutrient Supplementation in Conjunction With Standard Anti-Tuberculosis Therapy in Paediatric (6 Months-15 Years) New Pulmonary Tuberculosis Patients Completed NCT00801606 Phase 3 Zinc;Micronutrient without zinc;Micronutrient with zinc;Placebo
28 Impact of a Package of Intensive Smoking-cessation Interventions Versus Smoking-cessation Advice on Outcomes in Smear-positive Patients With Pulmonary Tuberculosis; a Randomised Controlled Trial (STB_RCT). Completed NCT01517022 Phase 3 nicotine replacement therapy
29 A Randomized Controlled Clinical Trial Comparing Daily Vs. Intermittent 6 - Month Short Course Chemotherapy in Reducing Failures & Emergence of Acquired Rifampicin Resistance (ARR) in Patients With HIV and Pulmonary Tuberculosis Completed NCT00933790 Phase 3 ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
30 A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening Regimen Comparing Two Months Moxifloxacin, Isoniazid, Rifampicin, Pyrazinamide Followed by Two Months Moxifloxacin, Isoniazid, Rifampicin Versus the Standard Regimen (Two Months Ethambutol, Isoniazid, Rifampicin, Pyrazinamide Followed by Four Months Isoniazid and Rifampicin) for the Treatment of Adults With Pulmonary Tuberculosis Completed NCT00864383 Phase 3 Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
31 Phase 3 Trial of Oral L-arginine and / or Vitamin D as Adjunctive Therapies in Pulmonary Tuberculosis in Papua Province, Indonesia. Completed NCT00677339 Phase 3 L-arginine;Vitamin D;Placebo L-arginine;Placebo Vitamin D
32 Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS Completed NCT00057434 Phase 3 multivitamin
33 A Double Blind, Randomized, Parallel, Placebo Control Design Study to Determine the Effect of Addition of Vitamin D to Conventional Anti TB Therapy Completed NCT00366470 Phase 3 A. 100,000 IU Cholecalciferol per dose of 3.3ml
34 A Phase 3 Open-label Trial Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Pulmonary Infection of Either Extensively Drug-resistant Tuberculosis (XDR-TB) or Treatment Intolerant / Non-responsive Multi-drug Resistant Tuberculosis (MDR-TB). Completed NCT02333799 Phase 3 Bedaquiline;PA-824;Linezolid
35 Trial of Adjunctive Vitamin D in Tuberculosis Treatment Completed NCT00419068 Phase 3 Cholecalciferol;Migliol Placebo Oil
36 Optimization of the TB Treatment Regimen Cascade Completed NCT02153528 Phase 3 double rimfampicin;Standard TB treatment
37 The Role of Nutritional Support and Diabetes During Treatment of Pulmonary TB: Two Randomized Nutritional Supplementation Trials in Tanzania Completed NCT00311298 Phase 3
38 A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of Anti-TB Treatment Completed NCT00130247 Phase 3 Ethambutol;Isoniazid;Pyrazinamide;Rifampin
39 Repurposing a Lipid Lowering Drug to Treat Tuberculosis: Effectiveness of Statins as Adjuvant to Treatment of Pulmonary Tuberculosis in Nigeria Recruiting NCT04721795 Phase 2, Phase 3 Atorvastatin with standard anti tuberculosis drugs;Anti tuberculosis drugs only
40 Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis Recruiting NCT03474198 Phase 2, Phase 3 Rifampicin;Isoniazid;Pyrazinamide;Ethambutol;Linezolid;Clofazimine;Rifapentine;Levofloxacin;Bedaquiline;Rifampicin
41 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion in HIV-infected and HIV-uninfected Adults Measured by FDG-PET/CT Recruiting NCT04147286 Phase 2, Phase 3 Atorvastatin 40mg;Placebo oral tablet
42 Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) Recruiting NCT03896685 Phase 3 Bedaquiline 100 MG;Delamanid 50 MG Oral Tablet;Clofazimine Pill;Linezolid Pill;Control arm MDR-TB regimen, designed according to latest WHO guidelines
43 Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB): A Clinical Trial Recruiting NCT02754765 Phase 3 Bedaquiline;Delamanid;Clofazimine;Levofloxacin;Moxifloxacin;Linezolid;Pyrazinamide;Control arm MDR-TB regimen, consistent with WHO guidelines
44 A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis Recruiting NCT02589782 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
45 Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD) Recruiting NCT04081077 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine
46 An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB) Active, not recruiting NCT03338621 Phase 2, Phase 3 Pretomanid;Bedaquiline;Moxifloxacin;Pyrazinamide;HRZE;HR
47 An International Multicentre Controlled Clinical Trial to Evaluate 1200mg and 1800mg Rifampicin Daily for Four Months in the Reduction of the Duration of Standard Treatment of Pulmonary Tuberculosis Active, not recruiting NCT02581527 Phase 3 Rifampicin;Isoniazid;Ethambutol;Pyrazinamide
48 A Phase 3 Partially-blinded, Randomized Trial Assessing the Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary Infection of Either Extensively Drug-resistant Tuberculosis (XDR-TB), Pre-XDR-TB or Treatment Intolerant or Non-responsive Multi-drug Resistant Tuberculosis (MDR-TB) Active, not recruiting NCT03086486 Phase 3 Pretomanid;Linezolid;Bedaquiline;Placebo Linezolid
49 Randomized, Placebo-controlled Study of Safety and Therapeutic Efficacy of the Drug FS-1 in the Oral Dosage Form in Drug-resistant Pulmonary Tuberculosis Active, not recruiting NCT02607449 Phase 3 FS-1;Placebo
50 Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin to 3 Months After Culture Conversion (Hi-DoRi-3): A Phase 3, Multicenter, Randomized, Open-label, Clinical Trial Not yet recruiting NCT04485156 Phase 3 High-dose rifampicin;Isoniazid;Pyrazinamide;Ethambutol;Rifampicin

Search NIH Clinical Center for Pulmonary Tuberculosis

Cochrane evidence based reviews: tuberculosis, pulmonary

Genetic Tests for Pulmonary Tuberculosis

Anatomical Context for Pulmonary Tuberculosis

The Foundational Model of Anatomy Ontology organs/tissues related to Pulmonary Tuberculosis:

19
Lungs

MalaCards organs/tissues related to Pulmonary Tuberculosis:

40
Liver, Heart, Skin, T Cells, Lung, Cortex, Lymph Node

Publications for Pulmonary Tuberculosis

Articles related to Pulmonary Tuberculosis:

(show top 50) (show all 30155)
# Title Authors PMID Year
1
Role of interferon-gamma release assays in the diagnosis of pulmonary tuberculosis in patients with advanced HIV infection. 61 54
20302657 2010
2
Interferon gamma gene +874A/T polymorphism and intracellular interferon gamma expression in pulmonary tuberculosis. 61 54
20004112 2010
3
Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis. 54 61
20007364 2010
4
Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans. 61 54
19771452 2010
5
Vitamin D receptor homozygote mutant tt and bb are associated with susceptibility to pulmonary tuberculosis in the Iranian population. 54 61
19482503 2010
6
P2X7 gene polymorphisms and risk assessment for pulmonary tuberculosis in Asian Indians. 61 54
20164546 2010
7
[Development and use of a domestic test system for diagnosis of tuberculous infection on the basis of quantitative analysis of interferon-gamma induction in whole blood samples in vitro, by using specific recombinant antigens]. 61 54
20201379 2010
8
Association between FokI polymorphism in vitamin D receptor gene and susceptibility to spinal tuberculosis in Chinese Han population. 61 54
20430254 2010
9
Rapid diagnosis of active pulmonary tuberculosis in the elderly using enzyme-linked immunospot assay for interferon-gamma. 61 54
20121995 2009
10
BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. 54 61
19715782 2009
11
Diagnosis of pulmonary tuberculosis among dialysis patients by enzyme-linked immunospot assay for interferon-gamma. 54 61
19474277 2009
12
Allelic polymorphism of cytokine genes during pulmonary tuberculosis. 54 61
20027321 2009
13
Plasma 1,25 dihydroxy vitamin D3 level and expression of vitamin d receptor and cathelicidin in pulmonary tuberculosis. 61 54
19219539 2009
14
[Case of pulmonary tuberculosis with miliary granules, mediastinal lymph node enlargement and elevation of soluble interleukin-2 receptor]. 61 54
19588853 2009
15
Adenosine deaminase activity and its isoenzymes in the sputum of patients with pulmonary tuberculosis. 54 61
19460251 2009
16
[A study on the haplotype of the solute carrier family 11 member 1 gene in Tibetan patients with pulmonary tuberculosis in China]. 61 54
19799071 2009
17
Analysis of discordance between the tuberculin skin test and the interferon-gamma release assay. 61 54
19335949 2009
18
Role played by human mannose-binding lectin polymorphisms in pulmonary tuberculosis. 61 54
19199550 2009
19
Effect of 1,25 dihydroxyvitamin D3 on intracellular IFN-gamma and TNF-alpha positive T cell subsets in pulmonary tuberculosis. 54 61
19091593 2009
20
Regulatory role of 1, 25-dihydroxyvitamin D3 and vitamin D receptor gene variants on intracellular granzyme A expression in pulmonary tuberculosis. 61 54
19014932 2009
21
[A case of pulmonary tuberculosis and tuberculous pleuritis during treatment with etanercept for rheumatoid arthritis]. 54 61
19260544 2009
22
[Modulatory effect of isoniazid and rifampicin in vitro on cytokine secretion in pulmonary tuberculosis]. 61 54
19697859 2009
23
[In vitro interferon-gamma induction in whole blood samples is a test for tuberculous infection in children and adolescents]. 54 61
19642569 2009
24
[Diagnostic value of interferon-gamma in the serum of patients with pulmonary tuberculosis and lung cancer diseases]. 54 61
19810179 2009
25
Compartmentalized bronchoalveolar IFN-gamma and IL-12 response in human pulmonary tuberculosis. 54 61
18848499 2009
26
The impact of HIV infection and CD4 cell count on the performance of an interferon gamma release assay in patients with pulmonary tuberculosis. 61 54
19156218 2009
27
Markedly-elevated serum CA125 in a woman with pulmonary tuberculosis. 61 54
19224069 2009
28
Impaired gamma interferon response to Mycobacterium vaccae antigens in patients with cavitary pulmonary tuberculosis. 61 54
18596204 2008
29
Characterization of human cellular immune responses to novel Mycobacterium tuberculosis antigens encoded by genomic regions absent in Mycobacterium bovis BCG. 61 54
18573897 2008
30
Differential expression of interleukin-4 (IL-4) and IL-4 delta 2 mRNA, but not transforming growth factor beta (TGF-beta), TGF-beta RII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment. 54 61
18579694 2008
31
Cytokine gene polymorphisms and cytokine levels in pulmonary tuberculosis. 54 61
18522869 2008
32
Regulatory role of promoter and 3' UTR variants of vitamin D receptor gene on cytokine response in pulmonary tuberculosis. 54 61
18231846 2008
33
Interleukin-12 receptor beta1 polymorphisms and nontuberculous mycobacterial lung diseases. 61 54
18493823 2008
34
Regulatory region polymorphisms of vitamin D receptor gene in pulmonary tuberculosis patients and normal healthy subjects of south India. 61 54
18397302 2008
35
Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. 61 54
18400912 2008
36
Enhancement of diagnostic efficiency by a gamma interferon release assay for pulmonary tuberculosis. 54 61
18400971 2008
37
Efficient testing of large pools of Mycobacterium tuberculosis RD1 peptides and identification of major antigens and immunodominant peptides recognized by human Th1 cells. 61 54
18400977 2008
38
A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study. 54 61
18492330 2008
39
Accuracy of an interferon-gamma release assay to detect active pulmonary and extra-pulmonary tuberculosis. 54 61
18284831 2008
40
Validity of the CA125 level in the differential diagnosis of pulmonary tuberculosis. 54 61
18219138 2008
41
Diagnostic accuracy of cytokine levels (TNF-alpha, IL-2 and IFN-gamma) in bronchoalveolar lavage fluid of smear-negative pulmonary tuberculosis patients. 61 54
17975298 2008
42
[Modulation of an antituberculous immune response in vitro, by using antigen-activated dendritic cells]. 61 54
18368774 2008
43
SLC11A1 (formerly NRAMP1) polymorphisms associated with multidrug-resistant tuberculosis. 61 54
17950034 2008
44
[Plasma levels of cytokines in patients with active infiltrative pulmonary tuberculosis]. 54 61
18819336 2008
45
Genetic polymorphisms in alveolar macrophage response-related genes, and risk of silicosis and pulmonary tuberculosis in Chinese iron miners. 61 54
17223386 2007
46
CD14 C(-159)T polymorphism is a risk factor for development of pulmonary tuberculosis. 54 61
18008256 2007
47
Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. 61 54
17950035 2007
48
Polymorphisms of interferon-gamma and interferon-gamma receptor 1 genes and pulmonary tuberculosis in Koreans. 54 61
17986123 2007
49
Rifampin levels, interferon-gamma release and outcome in complicated pulmonary tuberculosis. 54 61
17890156 2007
50
Promoter polymorphism of IL-18 gene in pulmonary tuberculosis in South Indian population. 54 61
17845300 2007

Variations for Pulmonary Tuberculosis

Expression for Pulmonary Tuberculosis

LifeMap Discovery
Genes differentially expressed in tissues of Pulmonary Tuberculosis patients vs. healthy controls: 35 (show all 44)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GBP6 guanylate binding protein family member 6 Blood + 4.38 0.000
2 ANKRD22 ankyrin repeat domain 22 Blood + 4.04 0.000
3 PDCD1LG2 programmed cell death 1 ligand 2 Blood + 4.03 0.000
4 CARMIL2 capping protein regulator and myosin 1 linker 2 Blood - 3.89 0.000
5 CD274 CD274 molecule Blood + 3.87 0.000
6 CD248 CD248 molecule Blood - 3.84 0.000
7 SPIB Spi-B transcription factor Blood - 3.81 0.000
8 LRRN3 leucine rich repeat neuronal 3 Blood - 3.61 0.000
9 LINC00668 long intergenic non-protein coding RNA 668 Blood + 3.60 0.000
10 C1QC complement C1q C chain Blood + 3.56 0.000
11 CR1 complement C3b/C4b receptor 1 (Knops blood group) Blood + 3.54 0.000
12 AEBP1 AE binding protein 1 Blood - 3.53 0.000
13 KREMEN1 kringle containing transmembrane protein 1 Blood + 3.49 0.000
14 CACNA1E calcium voltage-gated channel subunit alpha1 E Blood + 3.46 0.000
15 LGALSL galectin like Blood - 3.43 0.000
16 BATF2 basic leucine zipper ATF-like transcription factor 2 Blood + 3.42 0.000
17 PLEKHB1 pleckstrin homology domain containing B1 Blood - 3.40 0.000
18 CD22 CD22 molecule Blood - 3.38 0.000
19 BACH1 BTB domain and CNC homolog 1 Blood + 3.38 0.000
20 NAIP NLR family apoptosis inhibitory protein Blood + 3.34 0.000
21 EPHB6 EPH receptor B6 Blood - 3.30 0.000
22 DICER1 dicer 1, ribonuclease III Blood + 3.26 0.000
23 MVD mevalonate diphosphate decarboxylase Blood - 3.26 0.000
24 FBLN2 fibulin 2 Blood - 3.26 0.000
25 FBXL16 F-box and leucine rich repeat protein 16 Blood - 3.23 0.000
26 CR2 complement C3d receptor 2 Blood - 3.21 0.000
27 PRSS33 serine protease 33 Blood - 3.21 0.000
28 FGF13 fibroblast growth factor 13 Blood + 3.20 0.000
29 GNPNAT1 glucosamine-phosphate N-acetyltransferase 1 Blood - 3.19 0.000
30 RTKN2 rhotekin 2 Blood - 3.19 0.000
31 EPHA1 EPH receptor A1 Blood - 3.16 0.000
32 APOL6 apolipoprotein L6 Blood + 3.16 0.000
33 CRIP2 cysteine rich protein 2 Blood - 3.15 0.000
34 C1QB complement C1q B chain Blood + 3.15 0.000
35 CARD17 caspase recruitment domain family member 17 Blood + 3.14 0.000
36 SERINC5 serine incorporator 5 Blood - 3.12 0.000
37 HKDC1 hexokinase domain containing 1 Blood - 3.11 0.000
38 NT5E 5'-nucleotidase ecto Blood - 3.10 0.000
39 LINC00342 long intergenic non-protein coding RNA 342 Blood + 3.10 0.000
40 PMEPA1 prostate transmembrane protein, androgen induced 1 Blood - 3.09 0.000
41 FCGBP Fc fragment of IgG binding protein Blood - 3.07 0.000
42 SALL2 spalt like transcription factor 2 Blood - 3.06 0.000
43 GPA33 glycoprotein A33 Blood - 3.02 0.000
44 SLC27A5 solute carrier family 27 member 5 Blood - 3.00 0.000
Search GEO for disease gene expression data for Pulmonary Tuberculosis.

Pathways for Pulmonary Tuberculosis

Pathways related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 TLR2 SLC11A1 PGM1 MBL2 IL4 IL2RA
2
Show member pathways
13.73 INHA IL4 IL2RA IL2 IL18 IL12RB1
3
Show member pathways
13.61 IL4 IL2RA IL2 IL18 IL12RB1 IL12B
4
Show member pathways
13.48 TLR2 IL4 IL2RA IL2 IL18 IL12RB1
5
Show member pathways
13.4 IL4 IL2RA IL2 IL18 IL12RB1 IL12B
6
Show member pathways
13.36 IL4 IL2RA IL2 IL18 IL12RB1 IL12B
7
Show member pathways
13.27 TLR2 MBL2 IL2 IL18 IL12B IL10
8
Show member pathways
13.23 TLR2 IL4 IL2RA IL2 IFNGR1 IFNG
9
Show member pathways
12.93 IL4 IL2RA IL2 IL12B IL10 IFNG
10 12.92 IL4 IL2RA IL2 IL12RB1 IL12B IFNGR1
11
Show member pathways
12.87 TLR2 IL2RA IL2 IL18 IL12B IFNGR1
12 12.81 TLR2 IL12B IFNGR1 IFNG HLA-DRB1
13
Show member pathways
12.68 TLR2 IL4 IL2 IL10 IFNGR1 IFNG
14
Show member pathways
12.67 IL2 IL18 IL12RB1 IL12B IL10 IFNG
15 12.65 TLR2 IL4 IL2RA IL2 IL10 IFNG
16
Show member pathways
12.62 IL4 IL2RA IL2 IL18 IL12RB1 IL12B
17
Show member pathways
12.43 IL4 IL2RA IL2 IL12RB1 IL12B IL10
18
Show member pathways
12.41 IL2RA IL2 IL18 IL10 CCL3
19
Show member pathways
12.32 IL4 IL2RA IL2 IL18 IL12B IL10
20
Show member pathways
12.3 TLR2 IL4 IL12B IL10 IFNGR1 IFNG
21 12.26 VDR TLR2 IL18 IL12B IL10 IFNGR1
22
Show member pathways
12.23 TLR2 IL4 IL2RA IL2 IL18 IL12RB1
23
Show member pathways
12.22 TLR2 IL4 IFNGR1 IFNG
24 12.09 IL4 IL2RA IL2 IL10 IFNG
25 12.05 IL4 IL18 IL12B IL10
26 11.99 TLR2 IL12B IL10 IFNG
27 11.96 TLR2 IL18 IFNG HLA-DRB1 CCL3
28
Show member pathways
11.95 TLR2 IL4 IL12RB1 IL12B IFNG
29
Show member pathways
11.85 IL4 IL2RA IL2 IFNG
30 11.81 IL4 IL2 IFNG
31 11.79 TLR2 IL4 IL2RA IL10
32 11.76 IL2 IL10 IFNG
33 11.76 IL4 IL2RA IL2 IL18 IL12RB1 IL10
34 11.75 IL4 IL2RA IL2
35
Show member pathways
11.71 IL4 IL2RA IL2
36 11.68 IL4 IL12B CCL3
37
Show member pathways
11.67 IL2RA IL2 IFNG
38 11.64 TLR2 IL18 IL10 IFNG
39
Show member pathways
11.64 TLR2 IL2 IL18 IL12RB1 IL12B IL10
40 11.63 TLR2 IL18 IL12B
41 11.62 TLR2 IL18 IL12B IFNG
42 11.62 IL4 IL18 IL12B IL10 CCL3
43 11.58 IL4 IL2RA IL2 IL10 IFNG
44 11.55 IL2 IL12B IFNG
45 11.49 IL18 IL12B IL10 IFNG
46
Show member pathways
11.45 IL2RA IL2 IL10 IFNG CCL3
47 11.43 IL4 IL2RA IL2 IFNG
48 11.41 IL4 IL18 IL12B IFNG
49
Show member pathways
11.35 IL2RA IL12RB1 IL12B IFNG
50
Show member pathways
11.33 IL4 IL2RA IL2 IL18 IL12RB1 IL12B

GO Terms for Pulmonary Tuberculosis

Cellular components related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 PGM1 MBL2 INHA IL4 IL2 IL18
2 external side of plasma membrane GO:0009897 9.65 IL2RA IL12RB1 IL12B HLA-DRB1 ADA
3 cell surface GO:0009986 9.63 TLR2 MBL2 IL2RA IL12B HLA-DRB1 ADA
4 extracellular space GO:0005615 9.4 MBL2 INHA IL4 IL2 IL18 IL12B

Biological processes related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.34 TLR2 INHA IL4 IL18 IL12RB1 IL10
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.24 VDR TLR2 SLC11A1 IL4 IL2 IL18
3 immune system process GO:0002376 10.19 TLR2 MBL2 IL2RA IL2 HP HLA-DRB1
4 inflammatory response GO:0006954 10.09 TLR2 SLC11A1 IL2RA IL18 CCL3
5 defense response to bacterium GO:0042742 10.03 SLC11A1 MBL2 IL10 HP
6 cell-cell signaling GO:0007267 10.02 INHA IL2 IL18 CCL3
7 positive regulation of gene expression GO:0010628 10.01 VDR TLR2 SLC11A1 IL4 IL18 IFNGR1
8 negative regulation of inflammatory response GO:0050728 9.95 IL4 IL2RA IL2 IL10 ADA
9 cellular response to interferon-gamma GO:0071346 9.91 TLR2 IL12RB1 IL12B CCL3
10 interferon-gamma-mediated signaling pathway GO:0060333 9.89 IFNGR1 IFNG HLA-DRB1
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TLR2 IL18 IL12B
12 positive regulation of T cell proliferation GO:0042102 9.88 IL4 IL2RA IL2 IL12B
13 positive regulation of cytokine production GO:0001819 9.86 SLC11A1 IL10 IFNG
14 negative regulation of T cell proliferation GO:0042130 9.85 IL2RA IL10 HLA-DRB1
15 negative regulation of interferon-gamma production GO:0032689 9.85 INHA IL10 HLA-DRB1
16 positive regulation of tumor necrosis factor production GO:0032760 9.85 TLR2 IL12B IFNGR1 IFNG CCL3
17 interleukin-12-mediated signaling pathway GO:0035722 9.84 IL12RB1 IL12B IL10 IFNG
18 positive regulation of interleukin-12 production GO:0032735 9.83 TLR2 IL12B IFNG
19 positive regulation of B cell proliferation GO:0030890 9.83 IL4 IL2 ADA
20 positive regulation of interleukin-10 production GO:0032733 9.83 TLR2 IL4 IL12B
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 IL4 IL2 IL18 IL12B IFNG
22 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 TLR2 IL18 CCL3
23 positive regulation of defense response to virus by host GO:0002230 9.8 IL4 IL12RB1 IL12B
24 defense response to protozoan GO:0042832 9.8 SLC11A1 IL12B IL10
25 microglial cell activation GO:0001774 9.8 TLR2 IL4 IFNGR1 IFNG
26 positive regulation of T cell mediated cytotoxicity GO:0001916 9.79 IL12RB1 IL12B HLA-DRB1
27 natural killer cell activation GO:0030101 9.78 IL2 IL18 IL12B
28 positive regulation of interleukin-17 production GO:0032740 9.77 IL2 IL18 IL12B
29 regulation of regulatory T cell differentiation GO:0045589 9.77 IL2RA IL2 IFNG
30 positive regulation of MHC class II biosynthetic process GO:0045348 9.75 IL4 IL10 IFNG
31 positive regulation of T-helper 1 type immune response GO:0002827 9.74 SLC11A1 IL12RB1 IL12B
32 positive regulation of signaling receptor activity GO:2000273 9.73 IL10 IFNG
33 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.73 IFNGR1 IFNG
34 macrophage activation GO:0042116 9.73 SLC11A1 IL4
35 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.73 IL18 IL12B
36 cell activation GO:0001775 9.73 TLR2 CCL3
37 T-helper 1 type immune response GO:0042088 9.73 IL18 IL12B HLA-DRB1
38 positive regulation of inflammatory response GO:0050729 9.73 TLR2 IL2 IL18 IL12B IFNG CCL3
39 negative regulation of amyloid-beta clearance GO:1900222 9.72 IFNGR1 IFNG
40 interleukin-2-mediated signaling pathway GO:0038110 9.72 IL2RA IL2
41 response to molecule of bacterial origin GO:0002237 9.72 TLR2 IL10
42 positive regulation of interferon-gamma production GO:0032729 9.72 SLC11A1 IL2 IL18 IL12RB1 IL12B
43 negative regulation of T-helper 17 cell differentiation GO:2000320 9.71 IL4 IL2
44 positive regulation of isotype switching to IgG isotypes GO:0048304 9.71 IL4 IL2
45 interleukin-23-mediated signaling pathway GO:0038155 9.71 IL12RB1 IL12B
46 interferon-gamma production GO:0032609 9.71 IL18 IL12B
47 positive regulation of smooth muscle cell apoptotic process GO:0034393 9.7 IL12B IFNG
48 positive regulation of natural killer cell proliferation GO:0032819 9.7 IL18 IL12B
49 positive regulation of memory T cell differentiation GO:0043382 9.7 IL12RB1 IL12B HLA-DRB1
50 positive regulation of T-helper 17 type immune response GO:2000318 9.69 IL12RB1 IL12B

Molecular functions related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.35 VDR TLR2 PGM1 NAT2 MBL2 INHA
2 cytokine receptor activity GO:0004896 9.43 IL12RB1 IL12B IFNGR1
3 growth factor activity GO:0008083 9.35 INHA IL4 IL2 IL12B IL10
4 cytokine binding GO:0019955 9.33 IL12RB1 IL12B IFNGR1
5 interleukin-12 receptor binding GO:0005143 9.32 IL12RB1 IL12B
6 cytokine activity GO:0005125 9.23 INHA IL4 IL2 IL18 IL12B IL10

Sources for Pulmonary Tuberculosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....